Chapter 7 Application of Pet Imaging to Diagnosis of Alzheimer's Disease and Mild Cognitive Impairment1

International Review of Neurobiology

Volumn 84, Issue , 2009, Pages 133-149

  Noble, James M ^a,b,c   Scarmeas, Nikolaos ^b,c  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NewYork Presbyterian Hospital   (United States)

^c Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; FLUORODEOXYGLUCOSE F 18;

ALZHEIMER DISEASE; BAYES THEOREM; BRAIN METABOLISM; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; GLUCOSE METABOLISM; HUMAN; MILD COGNITIVE IMPAIRMENT; NEUROBIOLOGY; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALIDITY; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROBABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; COGNITIVE DEFECT; METHODOLOGY; SCINTISCANNING;

ALZHEIMER DISEASE; COGNITION DISORDERS; HUMANS; POSITRON-EMISSION TOMOGRAPHY;

EID: 66249119999     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(09)00407-3     Document Type: Review

References (68)

1. ADI. Common questions. In (2006). http://www.alz.co.uk/alzheimers/faq.html Accessed December 11, 2006
2. Alzheimer's Association. Alzheimer's Disease Facts and Figures (2008)
3. Barker W.W., Luis C., Harwood D., Loewenstein D., Bravo M., Ownby R., and Duara R. The effect of a memory screening program on the early diagnosis of Alzheimer disease. Alzheimers Dis. Assoc. Disord. 19 1 (2005) 1-7
4. Benson D.F., Kuhl D.E., Phelps M.E., Cummings J.L., and Tsai S.Y. Positron emission computed tomography in the diagnosis of dementia. Trans. Am. Neurol. Assoc. 106 (1981) 68-71
5. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82 4 (1991) 239-259
6. Brodaty H., Clarke J., Ganguli M., Grek A., Jorm A.F., Khachaturian Z., and Scherr P. Screening for cognitive impairment in general practice: Toward a consensus. Alzheimers Dis. Assoc. Disord. 12 1 (1998) 1-13
7. Brun A., and Englund E. Brain changes in dementia of Alzheimer's type relevant to new imaging diagnostic methods. Prog. Neuropsychopharmacol. Biol. Psychiatry 10 3-5 (1986) 297-308
8. Chetelat G., Desgranges B., de la Sayette V., Viader F., Eustache F., and Baron J.C. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease. Neurology 60 8 (2003) 1374-1377
9. Crystal H., Dickson D., Fuld P., Masur D., Scott R., Mehler M., Masdeu J., Kawas C., Aronson M., and Wolfson L. Clinico-pathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 38 11 (1988) 1682-1687
10. Cummings J.L. Alzheimer's disease. N. Engl. J. Med. 351 1 (2004) 56-67
11. Delacourte A., David J.P., Sergeant N., Buee L., Wattez A., Vermersch P., Ghozali F., Fallet-Bianco C., Pasquier F., Lebert F., Petit H., and Di Menza C. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 52 6 (1999) 1158-1165
12. de Leon M.J., Convit A., Wolf O.T., Tarshish C.Y., DeSanti S., Rusinek H., Tsui W., Kandil E., Scherer A.J., Roche A., Imossi A., Thorn E., et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-d-glucose/poitron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. USA 98 19 (2001) 10966-10971
13. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., et al. Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol. 6 8 (2007) 734-746
14. Edison P., Archer H.A., Hinz R., Hammers A., Pavese N., Tai Y.F., Hotton G., Cutler D., Fox N., Kennedy A., Rossor M., and Brooks D.J. Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study. Neurology 68 7 (2007) 501-508
15. Farkas T., Ferris S.H., Wolf A.P., De Leon M.J., Christman D.R., Reisberg B., Alavi A., Fowler J.S., George A.E., and Reivich M. 18F-2-deoxy-2-fluoro-d-glucose as a tracer in the positron emission tomographic study of senile dementia. Am. J. Psychiatry 139 3 (1982) 352-353
16. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 3 (1975) 189-198
17. Forsberg A., Engler H., Almkvist O., Blomquist G., Hagman G., Wall A., Ringheim A., Langstrom B., and Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 29 (2008) 1456-1465
18. Fortinsky R.H., Leighton A., and Wasson J.H. Primary care physicians' diagnostic, management, and referral practices for older persons and families affected by dementia. Res. Aging 17 (1995) 124-148
19. Foster N.L., Heidebrink J.L., Clark C.M., Jagust W.J., Arnold S.E., Barbas N.R., DeCarli C.S., Turner R.S., Koeppe R.A., Higdon R., and Minoshima S. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 130 Pt 10 (2007) 2616-2635
20. Friedland R.P., Brun A., and Budinger T.F. Pathological and positron emission tomographic correlations in Alzheimer's disease. Lancet 1 8422 (1985) 228
21. Friedland R.P., Budinger T.F., Ganz E., Yano Y., Mathis C.A., Koss B., Ober B.A., Huesman R.H., and Derenzo S.E. Regional cerebral metabolic alterations in dementia of the Alzheimer type: Positron emission tomography with [18F]fluorodeoxyglucose. J. Comput. Assist. Tomogr. 7 4 (1983) 590-598
22. Geldmacher D.S. Cost-effective recognition and diagnosis of dementia. Semin. Neurol. 22 1 (2002) 63-70
23. Grimes D.A., and Schulz K.F. Refining clinical diagnosis with likelihood ratios. Lancet 365 9469 (2005) 1500-1505
24. Gurland B.J., Wilder D.E., Lantigua R., Stern Y., Chen J., Killeffer E.H., and Mayeux R. Rates of dementia in three ethnoracial groups. Int. J. Geriatr. Psychiatry 14 6 (1999) 481-493
25. He W., Sengupta M., Velkoff V.A., and DeBarros K. 65+ in the United States: 2005 (2005), U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Aging and the U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census Bureau
26. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., and Evans D.A. Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch. Neurol. 60 8 (2003) 1119-1122
27. Hoffman J.M., Welsh-Bohmer K.A., Hanson M., Crain B., Hulette C., Earl N., and Coleman R.E. FDG PET imaging in patients with pathologically verified dementia. J. Nucl. Med. 41 11 (2000) 1920-1928
28. Jack Jr. C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., Knopman D.S., Boeve B.F., Klunk W.E., Mathis C.A., and Petersen R.C. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131 Pt 3 (2008) 665-680
29. Jagust W., Reed B., Mungas D., Ellis W., and Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?. Neurology 69 9 (2007) 871-877
30. Johnson K.A., Gregas M., Becker J.A., Kinnecom C., Salat D.H., Moran E.K., Smith E.E., Rosand J., Rentz D.M., Klunk W.E., Mathis C.A., Price J.C., et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann. Neurol. 62 3 (2007) 229-234
31. Kemppainen N.M., Aalto S., Wilson I.A., Nagren K., Helin S., Bruck A., Oikonen V., Kailajarvi M., Scheinin M., Viitanen M., Parkkola R., and Rinne J.O. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68 19 (2007) 1603-1606
32. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55 3 (2004) 306-319
33. Knopman D. Cerebrospinal fluid beta-amyloid and tau proteins for the diagnosis of Alzheimer disease. Arch. Neurol. 58 3 (2001) 349-350
34. Knopman D.S., DeKosky S.T., Cummings J.L., Chui H., Corey-Bloom J., Relkin N., Small G.W., Miller B., and Stevens J.C. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 9 (2001) 1143-1153
35. Lockhart A., Lamb J.R., Osredkar T., Sue L.I., Joyce J.N., Ye L., Libri V., Leppert D., and Beach T.G. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 130 Pt 10 (2007) 2607-2615
36. Manly J.J., Bell-McGinty S., Tang M.X., Schupf N., Stern Y., and Mayeux R. Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community. Arch. Neurol. 62 11 (2005) 1739-1746
37. Manly J.J., Tang M.X., Schupf N., Stern Y., Vonsattel J.P., and Mayeux R. Frequency and course of mild cognitive impairment in a multiethnic community. Ann. Neurol. 63 (2008) 494-506
38. Matsuda H. The role of neuroimaging in mild cognitive impairment. Neuropathology 27 6 (2007) 570-577
39. Mayeux R. Apolipoprotein E, Alzheimer disease, and African Americans. Arch. Neurol. 60 2 (2003) 161-163
40. Mayeux R. Epidemiology of neurodegeneration. Annu. Rev. Neurosci. 26 (2003) 81-104
41. McGeer P.L., Kamo H., Harrop R., McGeer E.G., Martin W.R., Pate B.D., and Li D.K. Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer's disease. Neurology 36 12 (1986) 1569-1574
42. McGeer P.L., Kamo H., Harrop R., Li D.K., Tuokko H., McGeer E.G., Adam M.J., Ammann W., Beattie B.L., Calne D.B., et al. Positron emission tomography in patients with clinically diagnosed Alzheimer's disease. CMAJ 134 6 (1986) 597-607
43. McGeer E.G., McGeer P.L., Harrop R., Akiyama H., and Kamo H. Correlations of regional postmortem enzyme activities with premortem local glucose metabolic rates in Alzheimer's disease. J. Neurosci. Res. 27 4 (1990) 612-619
44. McGeer E.G., Peppard R.P., McGeer P.L., Tuokko H., Crockett D., Parks R., Akiyama H., Calne D.B., Beattie B.L., and Harrop R. 18Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer cases, including 13 serial scans. Can. J. Neurol. Sci. 17 1 (1990) 1-11
45. McMahon P.M., Araki S.S., Sandberg E.A., Neumann P.J., and Gazelle G.S. Cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology 228 2 (2003) 515-522
46. Mielke R., Schroder R., Fink G.R., Kessler J., Herholz K., and Heiss W.D. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol. 91 2 (1996) 174-179
47. Mintun M.A., Larossa G.N., Sheline Y.I., Dence C.S., Lee S.Y., Mach R.H., Klunk W.E., Mathis C.A., DeKosky S.T., and Morris J.C. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67 3 (2006) 446-452
48. Morris J.C., Storandt M., McKeel Jr. D.W., Rubin E.H., Price J.L., Grant E.A., and Berg L. Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurology 46 3 (1996) 707-719
49. Morris J.C., Storandt M., Miller J.P., McKeel D.W., Price J.L., Rubin E.H., and Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Arch. Neurol. 58 3 (2001) 397-405
50. Mortimer J.A., Snowdon D.A., and Markesbery W.R. Head circumference, education and risk of dementia: Findings from the Nun Study. J. Clin. Exp. Neuropsychol. 25 5 (2003) 671-679
51. Mosconi L., Perani D., Sorbi S., Herholz K., Nacmias B., Holthoff V., Salmon E., Baron J.C., De Cristofaro M.T., Padovani A., Borroni B., Franceschi M., et al. MCI conversion to dementia and the APOE genotype: A prediction study with FDG-PET. Neurology 63 12 (2004) 2332-2340
52. Nestor P.J., Fryer T.D., Smielewski P., and Hodges J.R. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann. Neurol. 54 3 (2003) 343-351
53. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC-CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 357 9251 (2007) 169-175
54. Ng S., Villemagne V.L., Berlangieri S., Lee S.T., Cherk M., Gong S.J., Ackermann U., Saunder T., Tochon-Danguy H., Jones G., Smith C., O'Keefe G., et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J. Nucl. Med. 48 4 (2007) 547-552
55. Patwardhan M.B., McCrorg D.C., Matchar D.B., Samsa G.P., and Rutschmann O.T. Alzheimer disease: Operating characteristics of PET-A meta-analysis. Radiology 231 1 (2004) 73-80
56. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., and Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch. Neurol. 56 3 (1999) 303-308
57. Petersen R.C., Stevens J.C., Ganguli M., Tangalos E.G., Cummings J.L., and DeKosky S.T. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 9 (2001) 1133-1142
58. Phelps M.E., Mazziotta J.C., and Huang S.C. Study of cerebral function with positron computed tomography. J. Cereb. Blood Flow Metab. 2 2 (1982) 113-162
59. Pike K.E., Savage G., Villemagne V.L., Ng S., Moss S.A., Maruff P., Mathis C.A., Klunk W.E., Masters C.L., and Rowe C.C. Beta-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain 130 Pt 11 (2007) 2837-2844.56
60. Pimlott N.J., Siegel K., Persaud M., Slaughter S., Cohen C., Hollingworth G., Cummings S., Drummond N., Dalziel W., Sylvius J., Pringle D., and Eliasziw T. Management of dementia by family physicians in academic settings. Can. Fam. Physician 52 9 (2006) 1108-1109
61. Riedel-Heller S.G., Schork A., Matschinger H., and Angermeyer M.C. The role of referrals in diagnosing dementia at the primary care level. Int. Psychogeriatr. 11 3 (1999) 251-262
62. Silverman D.H., Gambhir S.S., Huang H.W., Schwimmer J., Kim S., Small G.W., Chodosh J., Czernin J., and Phelps M.E. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: A comparison of predicted costs and benefits. J. Nucl. Med. 43 2 (2002) 253-266
63. Silverman D.H., Small G.W., Chang C.Y., Lu C.S., Kung De Aburto M.A., Chen W., Czernin J., Rapoport S.I., Pietrini P., Alexander G.E., Schapiro M.B., Jagust W.J., et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 286 17 (2001) 2120-2127
64. Tang M.X., Stern Y., Marder K., Bell K., Gurland B., Lantigua R., Andrews H., Feng L., Tycko B., and Mayeux R. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 279 10 (1998) 751-755
65. UN. The United Nations Population Division. World Population Prospects: The 2002 Revision (2003), United Nations, New York
66. US Preventive Services Task Force. Screening for dementia: Recommendations and rationale. Guide to Clinical Prevention Services. Ann. Intern. Med. 139 (2003) 925-926
67. Wimo A., Winblad A., and Jönsson A. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimers Dement. J. Alzheimers Assoc. 3 2 (2007) 81-91
68. World Health Organization. Mental Health Atlas (2005) 471